Literature DB >> 2859983

Multiple mechanisms of somatostatin inhibition of adrenocorticotropin release from mouse anterior pituitary tumor cells.

T Reisine.   

Abstract

The release of ACTH from a clonal cell line of the mouse anterior pituitary (AtT-20/D16-16) can be stimulated by forskolin, 8-bromo-cAMP, and K+. SRIF and its structurally related analogs are very potent inhibitors of the ACTH release response to these secretagogues. The potency of SRIF, its analogs, and somatostatin-28 to inhibit stimulated ACTH release is relatively the same for each of these three secretagogues. The mechanisms by which SRIF regulates the secretion of ACTH can be differentiated by various pharmacological manipulations. Pretreatment of AtT-20 cells with SRIF (10(-7) M) desensitizes SRIF's inhibition of forskolin but not K+ or 8-bromo-cAMP-stimulated ACTH release. Pertussis toxin pretreatment abolishes SRIF's inhibition of forskolin-stimulated ACTH release but not SRIF's inhibition of the ACTH release response to K+ or 8-bromo-cAMP. In contrast, increasing the calcium concentration in the medium reduces SRIF's inhibition of K+ but not forskolin or 8-bromo-cAMP-stimulated ACTH release. These results suggest that SRIF regulates ACTH release from AtT-20 cells through multiple mechanisms. If SRIF acts through a single receptor to produce its effects on ACTH release, then the data imply that the SRIF receptor is coupled to more than one second messenger system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859983     DOI: 10.1210/endo-116-6-2259

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  Colocalization of somatostatin receptors with DARPP-32 in cortex and striatum of rat brain.

Authors:  Padmesh S Rajput; Geetanjali Kharmate; Ujendra Kumar
Journal:  J Mol Neurosci       Date:  2011-11-25       Impact factor: 3.444

2.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

Review 3.  Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action.

Authors:  E A Woltering; J C Watson; R C Alperin-Lea; C Sharma; E Keenan; D Kurozawa; R Barrie
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  Purification of a putative brain somatostatin receptor.

Authors:  H T He; K Johnson; K Thermos; T Reisine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  Dual regulation of ACTH secretion by guanine nucleotides in permeabilized AtT-20 cells.

Authors:  A Luini; M A De Matteis
Journal:  Cell Mol Neurobiol       Date:  1988-03       Impact factor: 5.046

6.  Amino acids and amines stimulate gastrin release from canine antral G-cells via different pathways.

Authors:  J DelValle; T Yamada
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Sensitivity of rat pancreatic A and B cells to somatostatin.

Authors:  F C Schuit; M P Derde; D G Pipeleers
Journal:  Diabetologia       Date:  1989-03       Impact factor: 10.122

8.  Mediation by SRIF1 receptors of the contractile action of somatostatin in rat isolated distal colon; studies using some novel SRIF analogues.

Authors:  E S McKeen; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

9.  Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome.

Authors:  P Ruszniewski; F Girard; R Benamouzig; M Mignon; S Bonfils
Journal:  Gut       Date:  1988-06       Impact factor: 23.059

10.  Somatostatin-mediated inhibitory postsynaptic potential in sympathetically denervated guinea-pig submucosal neurones.

Authors:  K Z Shen; A Surprenant
Journal:  J Physiol       Date:  1993-10       Impact factor: 5.182

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.